Cargando…

The effectiveness of controlled ovarian stimulation with tamoxifen for patients with estrogen‐sensitive breast cancer: A systematic review and meta‐analysis

PURPOSE: Tamoxifen is used for the suppression of estrogen‐sensitive tumor recurrence in oocyte retrieval cycles. This meta‐analysis aimed to evaluate the quality of controlled ovarian stimulation (COS) with co‐administration of gonadotropins and tamoxifen (COS with tamoxifen). METHODS: PubMed, Emba...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yoshida, Tsukasa, Takahashi, Osamu, Suzuki, Yoko, Ota, Erika, Hirata, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10517303/ https://www.ncbi.nlm.nih.gov/pubmed/37745035 http://dx.doi.org/10.1002/rmb2.12543

Ejemplares similares

FOXC1 is associated with estrogen receptor alpha and affects sensitivity of tamoxifen treatment in breast cancer
por: Wang, Jinhua, et al.
Publicado: (2016)

Tamoxifen resistance alters sensitivity to 5-fluorouracil in a subset of estrogen receptor-positive breast cancer
por: Watanabe, Takayuki, et al.
Publicado: (2021)

Resuming Sensitivity of Tamoxifen-Resistant Breast Cancer Cells to Tamoxifen by Tetrandrine
por: Wang, Yuntao, et al.
Publicado: (2021)

Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen
por: Chen, I-Chun, et al.
Publicado: (2017)

Estrogen receptor β represses Akt signaling in breast cancer cells via downregulation of HER2/HER3 and upregulation of PTEN: implications for tamoxifen sensitivity
por: Lindberg, Karolina, et al.
Publicado: (2011)

Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

Lnc-DC promotes estrogen independent growth and tamoxifen resistance in breast cancer
por: Peng, Wan-Xin, et al.
Publicado: (2021)

Ovarian cysts in women receiving tamoxifen for breast cancer
por: Mourits, M J E, et al.
Publicado: (1999)

Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells
por: Moon, Seo Yun, et al.
Publicado: (2021)

Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancer
por: Gjerde, Jennifer, et al.
Publicado: (2010)

Estrogen Receptor Expression and Estrogen Receptor‐independent Cytotoxic Effects of Tamoxifen on Malignant Rhabdoid Tumor Cells in vitro
por: Koshida, Shigeki, et al.
Publicado: (2002)

Silencing of syndecan-binding protein enhances the inhibitory effect of tamoxifen and increases cellular sensitivity to estrogen
por: Zhang, Jun, et al.
Publicado: (2018)

Tamoxifen Regulates Cell Fate Through Mitochondrial Estrogen Receptor Beta in Breast Cancer
por: Razandi, Mahnaz, et al.
Publicado: (2012)

Phosphorylation of estrogen receptor α at serine 118 is correlated with breast cancer resistance to tamoxifen
por: CHEN, MING, et al.
Publicado: (2013)

The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells
por: Chang, Bo Yoon, et al.
Publicado: (2011)

Raptor localization predicts prognosis and tamoxifen response in estrogen receptor-positive breast cancer
por: Bostner, Josefine, et al.
Publicado: (2017)

Influence of Tamoxifen‐Medroxyprogesterone Sequential Therapy on Estrogen and Progesterone Receptor Contents of Breast Cancer
por: Noguchi, Shinzaburo, et al.
Publicado: (1989)

A Role for Estrogen Receptor Phosphorylation in the Resistance to Tamoxifen
por: de Leeuw, Renée, et al.
Publicado: (2011)

Tamoxifen non-estrogen receptor mediated molecular targets
por: Bogush, Tatiana, et al.
Publicado: (2012)

Loss of B-cell translocation gene 2 expression in estrogen receptor-positive breast cancer predicts tamoxifen resistance
por: Takahashi, Maiko, et al.
Publicado: (2014)

Correction: Tamoxifen and Ovarian Function
por: Berliere, Martine, et al.
Publicado: (2013)

BreastDefend enhances effect of tamoxifen in estrogen receptor-positive human breast cancer in vitro and in vivo
por: Cheng, Shujie, et al.
Publicado: (2017)

Tamoxifen with ovarian function suppression versus tamoxifen alone as an adjuvant treatment for premenopausal breast cancer: a meta-analysis of published randomized controlled trials
por: Yan, Shunchao, et al.
Publicado: (2015)

Predicting prognosis using molecular profiling in estrogen receptor-positive breast cancer treated with tamoxifen
por: Loi, Sherene, et al.
Publicado: (2008)

Effects of low-dose tamoxifen on breast cancer biomarkers Ki-67, estrogen and progesterone receptors
por: de Sousa, Juarez Antônio, et al.
Publicado: (2006)

miR-342 is associated with estrogen receptor-α expression and response to tamoxifen in breast cancer
por: HE, YUE-JUN, et al.
Publicado: (2013)

Anticancer effect of metformin on estrogen receptor-positive and tamoxifen-resistant breast cancer cell lines
por: KIM, JINKYOUNG, et al.
Publicado: (2016)

Nogo-B receptor increases the resistance to tamoxifen in estrogen receptor-positive breast cancer cells
por: Gao, Pin, et al.
Publicado: (2018)

How do we increase uptake of tamoxifen and other anti-estrogens for breast cancer prevention?
por: Crew, Katherine D., et al.
Publicado: (2017)

Synthesis of Tamoxifen‐Artemisinin and Estrogen‐Artemisinin Hybrids Highly Potent Against Breast and Prostate Cancer
por: Fröhlich, Tony, et al.
Publicado: (2020)

Inhibition of tamoxifen's therapeutic effects by emodin in estrogen receptor-positive breast cancer cell lines
por: Kim, Yun Gyoung, et al.
Publicado: (2019)

Prognostic significance of autophagy related genes in estrogen receptor positive tamoxifen treated breast cancer
por: Mishra, Alok, et al.
Publicado: (2020)

Role of SALL4 and Nodal in the prognosis and tamoxifen resistance of estrogen receptor-positive breast cancer
por: Boustan, Arad, et al.
Publicado: (2021)

Tamoxifen Response at Single Cell Resolution in Estrogen Receptor-Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

Tamoxifen Response at Single-Cell Resolution in Estrogen Receptor–Positive Primary Human Breast Tumors
por: Kim, Hyunsoo, et al.
Publicado: (2023)

HER4 expression in estrogen receptor-positive breast cancer is associated with decreased sensitivity to tamoxifen treatment and reduced overall survival of postmenopausal women
por: Wege, Anja Kathrin, et al.
Publicado: (2018)

The rate of estrogen receptor‐conversion associated with tumor progression in estrogen receptor‐positive breast cancer patients following adjuvant Tamoxifen administration
por: Djahansouzi, Sirus, et al.
Publicado: (2021)

Involution of Breast Lobules, Mammographic Breast Density and Prognosis Among Tamoxifen-Treated Estrogen Receptor-Positive Breast Cancer Patients
por: Mullooly, Maeve, et al.
Publicado: (2019)

Annexin-A1 and caldesmon are associated with resistance to tamoxifen in estrogen receptor positive recurrent breast cancer
por: De Marchi, Tommaso, et al.
Publicado: (2015)

Tamoxifen stimulates arachidonic acid release from rat liver cells by an estrogen receptor-independent, non-genomic mechanism
por: Levine, Lawrence
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_cal1nqik7q792i0davretl6g3f